New Options in Platinum Resistant Ovarian Cancer

Video Transcription

Video Summary

The video is a webinar entitled "New Options in Platinum-Resistant Ovarian Cancer" and is sponsored in part by an educational grant from Imogen. It is hosted by Wendell Naumann, a gynecologic oncologist, and co-chaired by Flora Backus. The webinar discusses the latest advancements and updates in the treatment of platinum-resistant ovarian cancer. Dr. David O'Malley, a professor and director of the G1 Oncology division, joins the discussion. The webinar covers topics such as the approach to ovarian cancer, sequencing of platinum resistance patients, the use of weekly paclitaxel, targeted therapies, and ongoing clinical trials. Dr. O'Malley presents data from the Forward II trial, which investigated the use of MIRV-BEV, an antibody-drug conjugate, in platinum-resistant ovarian cancer. The trial showed promising response rates, with a 44% objective response rate and a median duration of response of almost 10 months. The webinar also discusses the safety profile of MIRV-BEV and its inclusion in the NCCN guidelines as a 2B recommendation. The upcoming trials and potential future options for the treatment of ovarian cancer are highlighted as well. The video concludes with a Q&A session, where questions about hypertension management and the reversibility of ocular toxicity are addressed. The webinar encourages clinicians to consider clinical trials and to test for biomarkers to identify patients eligible for novel therapies. The video is available on the IGCS 360 portal for viewing.

Keywords

webinar

Platinum-Resistant Ovarian Cancer

advancements

treatment

paclitaxel

clinical trials

MIRV-BEV